Skip to main content

TA-TMA Testing: Faster Results and a Comprehensive Approach

 TA-TMA Transplant-associated thrombotic microangiopathy

Eurofins Viracor's TA-TMA (Transplant-associated thrombotic microangiopathy) testing stands out for its comprehensiveness, offering clinicians a complete assessment of complement pathway regulation and potential deregulation with validated assays for Eculizumab, CH50, and sC5b-9.

Our comprehensive approach ensures that clinicians receive detailed results across all three critical areas, empowering them to make informed decisions about patient treatment promptly, thanks to our industry-leading 24 hour turnaround time.

More About the Eurofins-Viracor TA-TMA Assays:

"Routine TA-TMA screening and complement-blocking therapies have markedly improved the outcomes for high-risk TA-TMA patients, and studies1 suggests that additional patients may benefit from TA-TMA treatment. This study provides further support for prospective TA-TMA screening as an integral tool for identifying patients at greatest risk for organ injury and death from TA-TMA."1

Eculizumab, performed with 24 hour TAT on Tuesday-Saturday, assesses the Eculizumab levels in serum or plasma. Crucially, they specifically measure the free form, not bound to endogenous C5. Swift results aid in personalized patient care and treatment optimization.

Explore an in-depth study of TA-TMA...

"Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?"

Presented by:
Dr. Sonata Jodele, MD Research Professor
Division of Bone Marrow Transplantation and Immune Deficiency
Cincinnati Children’s Hospital Medical Center

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a clinical syndrome of endothelial injury resulting in microangiopathic hemolytic anemia, consumptive thrombocytopenia, and microvascular thrombosis, which cause organ and tissue ischemia. Multiple insults after hematopoietic stem cell transplantation (HSCT) can trigger TA-TMA in susceptible individuals...READ MORE


  1. Transplant Cell Ther. 2022 July ; 28(7): 392.e1–392.e9. doi:10.1016/j.jtct.2022.04.019

About the author


Back to top